M
MitoRx Therapeutics
Biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction
About MitoRx Therapeutics
MitoRx Therapeutics is a pioneering biotech company focused on developing first-in-class therapeutics that target mitochondrial dysfunction. The company operates in the healthcare and biotechnology market, specifically addressing rare diseases such as muscular dystrophy and neurodegenerative disorders. MitoRx Therapeutics serves patients suffering from these debilitating conditions, offering them hope through innovative treatments that reverse mitochondrial dysfunction and arrest disease progression. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their therapeutic solutions. Revenue is generated through partnerships, licensing agreements, and direct sales of their approved drugs. The leadership team boasts extensive experience in biotech, with backgrounds in business development, intellectual property, and clinical program management.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Exeter, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Oxford Technology
LongevityTech.fund
Wren Capital
Future Planet Capital
Fink Family Office
Science Angel Syndicate- OHOshen Holdings
Empirical Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MitoRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MitoRx Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.